Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Dicerna Pharmaceuticals, Inc. (DRNA)

38.22   0 (0%) 05-16 00:57
Open: 38.21 Pre. Close: 38.22
High: 38.24 Low: 38.21
Volume: 5,540,084 Market Cap: 2,978(M)
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts. As of December 27, 2021, Dicerna Pharmaceuticals, Inc. operates as a subsidiary of Novo Nordisk A/S.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: - -
Low: - -
Close: - -

Technical analysis

as of: 2022-02-14 10:19:02 AM
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 44.65     One year: 44.66
Support: Support1: 38.2    Support2: 31.79
Resistance: Resistance1: 38.22    Resistance2: 38.24
Pivot: 38.22
Moving Average: MA(5): 38.22     MA(20): 38.22
MA(100): 31.45     MA(250): 29.95
MACD: MACD(12,26): 0.1     Signal(9): 0.2
Stochastic oscillator: %K(14,3): 33.3     %D(3): 33.3
RSI: RSI(14): 81.9
52-week: High: 40.13  Low: 19.05
Average Vol(K): 3-Month: 0 (K)  10-Days: 0 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ DRNA ] has closed Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 46 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Fri, 13 May 2022
Direct RNA targeted in situ sequencing for transcriptomic profiling in tissue | Scientific Reports -

Thu, 18 Nov 2021
Pre-Market Most Active for Nov 18, 2021 : SEV, CLOV, LCID, DRNA, RAAS, PROG, M, BABA, NVDA, VIPS, IONQ, MT - Nasdaq

Thu, 18 Nov 2021
DRNA Stock Hits Stratosphere On $3.3 Billion Takeover - Investor's Business Daily

Fri, 15 Oct 2021
Dicerna Announces Data to Be Presented at American Society of Nephrology (ASN) Kidney Week 2021 - Yahoo Finance

Wed, 22 Sep 2021
Dicerna Announces New Executive Leadership Appointments - Business Wire

Fri, 06 Aug 2021
Why Dicerna Pharmaceuticals Stock Is Tumbling on Friday - The Motley Fool

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 78 (M)
Shares Float 60 (M)
% Held by Insiders 7.4 (%)
% Held by Institutions 88.5 (%)
Shares Short 4,770 (K)
Shares Short P.Month 2,880 (K)

Stock Financials

EPS -1.63
EPS Est Next Qtl -0.69
EPS Est This Year -2.71
EPS Est Next Year -2.76
Book Value (p.s.) 1.37
Profit Margin (%) -64.6
Operating Margin (%) -62.9
Return on Assets (ttm) -10.5
Return on Equity (ttm) -95.3
Qtrly Rev. Growth 28.7
Gross Profit (p.s.) -0.53
Sales Per Share 2.47
EBITDA (p.s.) -1.5
Qtrly Earnings Growth 0
Operating Cash Flow 21 (M)
Levered Free Cash Flow -46 (M)

Stock Valuations

PE Ratio -23.45
PEG Ratio 0
Price to Book value 27.69
Price to Sales 15.44
Price to Cash Flow 141.45

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.